spacer
home > ebr > summer 2020 > a conversation with an expert in drug development
PUBLICATIONS
European Biopharmaceutical Review

A Conversation with an Expert in Drug Development

EBR: What can you tell us about the main areas of research being undertaken for COVID-19 therapies?

Colin Orford: Researchers are working to develop COVID-19 therapies passionately and compassionately. Fortunately, the list of candidates in development is robust and reflects interest in treating all stages of the disease – interventions for mild, moderate, and severe disease states. Target participant populations span ambulatory and hospitalised patients as well as post-exposure. We are starting to see a shift in focus from vaccine development and treatments for those most critically ill, to treatments for those who suffer only mild to moderate symptoms.

What is the likelihood that we will have an effective treatment in advance of a widely distributed vaccine, which we understand can take 18 months if all goes well?

Work is progressing on both treatments and vaccines in parallel. However, the need for an effective treatment has been top of mind for researchers. I expect that we will have a treatment before we have a vaccine as the industry is investigating the feasibility of repurposing existing, approved medications that either look to reduce viral replication or to target the underlying immunological and inflammatory processes. There is also a lot happening behind the scenes. There are numerous companies with drug candidates still ‘on the bench’ that are seeking funding at this point.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Colin Orford, PhD, Senior Vice President, is Head of Drug Development Services at ICON plc. He has 29 years of experience in the pharma sector gained at GSK (SmithKline Beecham), Novartis, Quintiles, and Eisai, which combines development strategy with operational execution. Colin has 20 years of hands-on drug development experience having led multiple R&D project teams, and has worked across all stages of the development spectrum from preclinical through to Phase IIIb. He has been responsible for transitioning multiple molecules in the neurosciences area, from preclinical (candidate selection), through proof of concept, and into late phase development. He has also led a number of Phase III teams and been involved in several new drug applications and marketing authorisation application submissions.

Colin leads ICON’s drug development and consulting team, is a member of the commercial leadership team, and a member of ICON’s clinical research services, senior leadership team. He has developed and established ICON’s due diligence capabilities and has continued to focus on developing new models of drug development collaborations which range from fully virtual development, with small companies, through to externalised development for larger pharma.
spacer
Dr Colin Orford
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Evolution Summit Press Release

“Many clinical trials today face delays because of difficulties in recruiting the required number of patients within the timeline. Sponsors need to look at other regions outside the US and Western Europe, that have access to a large pool of motivated patients, without compromising quality or anything else,” says Roman Hrynchuk, Chief Operating Officer, SanaClis. SanaClis was a solution provider at the Marcus Evans Evolution Summit March 2020.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement